Primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology, Kensey Nash manufactures and sells through partners medical device parts in cardiology, orthopedic, sports medicine, spinal and general surgery. Already Publicly traded befoe becoming SBIR Involved, at the time of acquisition the firm had grown to some 325 employees with sales of approximately $100M. Since its founding Kensey Nash had developed an important arterial closure device in the world using resorbable collagen, synthetic polymer technologies and device engineering expertise. The company had developed a large catalog of technologies used to create high-quality products and devices. Its mechanical device, collagen processing, synthetic polymer, bone mineral, extracellular matrix and other products provide a solid foundation to develop an expansive variety of innovations in regenerative medicine. The purchase by DSM of Kensey Nash strengthens and complements DSM's biomedical business and capabilities, while clearly meeting DSM's financial and strategic criteria. For DSM Biomedical the acquisition of Kensey Nash is an important step in realizing its strategic ambition to build strong positions in bio-passive, bio-active and bio-interactive materials, strengthing DSM's existing position in the market for bio-passive (medical coatings and polymers) and the emerging market for bio-active (resorbable polymers and drug delivery) materials. It also provides DSM with a strong position and pipeline of new technologies in the developing field of regenerative medicine and tissue engineering (bio-interactive materials).
